Certara (NASDAQ:CERT) Upgraded at UBS Group

UBS Group upgraded shares of Certara (NASDAQ:CERT) to a hold rating in a research report sent to investors on Wednesday morning,Zacks reports.

CERT has been the subject of a number of other reports. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. Barclays lifted their price objective on Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.45.

Certara Stock Performance

NASDAQ:CERT opened at $9.36 on Wednesday. The company’s 50-day moving average price is $8.27 and its 200-day moving average price is $6.76. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.43 billion, a P/E ratio of -20.80 and a beta of 1.42. Certara has a twelve month low of $4.45 and a twelve month high of $13.88.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm’s revenue was down 10.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.07 EPS. On average, sell-side analysts forecast that Certara will post 0.22 earnings per share for the current fiscal year.

Institutional Trading of Certara

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Certara during the 2nd quarter worth about $123,259,000. Dimensional Fund Advisors LP lifted its position in Certara by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after buying an additional 175,024 shares during the last quarter. Haveli Investment Management LLC acquired a new position in Certara in the second quarter valued at about $48,470,000. Jefferies Financial Group Inc. purchased a new position in Certara during the second quarter worth about $46,446,000. Finally, Fort Washington Investment Advisors Inc. OH boosted its stake in Certara by 17.7% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,675,543 shares of the company’s stock worth $15,251,000 after buying an additional 402,720 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.